PTGS2 and depressive symptom measurement: Future research should prioritise evaluating these inhibitors in preclinical models of depression, examining their effects on ferroptosis markers (e.g., GPX4, PTGS2, lipid ROS), synaptic integrity, and depression‐related behaviours.